Mostrar el registro sencillo del ítem

dc.contributor.authorRivero-Menendez, Olga 
dc.contributor.authorSoto-Debran, Juan Carlos
dc.contributor.authorCuenca-Estrella, Manuel 
dc.contributor.authorAlastruey-Izquierdo, Ana 
dc.date.accessioned2021-05-27T20:38:29Z
dc.date.available2021-05-27T20:38:29Z
dc.date.issued2021-03-20
dc.identifier.citationJ Fungi (Basel). 2021;7(3):232.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/13033
dc.description.abstractIbrexafungerp is a new orally-available 1,3-β-D-glucan synthesis inhibitor in clinical development. Its in vitro activity and that of amphotericin B, voriconazole, and micafungin were evaluated against a collection of 168 clinical isolates of Aspergillus spp., including azole-susceptible and azole-resistant (Cyp51A mutants) Aspergillus fumigatus sensu stricto (s.s.) and cryptic species of Aspergillus belonging to six species complexes showing different patterns of antifungal resistance, using EUCAST and CLSI antifungal susceptibility testing reference methods. Ibrexafungerp displayed low geometric means of minimal effective concentrations (MECs) against A. fumigatus s.s. strains, both azole susceptible (0.040 mg/L by EUCAST and CLSI versus 1.231 mg/L and 0.660 mg/L for voriconazole, respectively) and azole resistant (0.092 mg/L and 0.056 mg/L, EUCAST and CLSI, while those for voriconazole were 2.144 mg/L and 2.000 mg/L). Ibrexafungerp was active against most of the cryptic species of Aspergillus tested, yielding MEC values only comparable to those of micafungin. Nevertheless, this new compound exhibited a moderate activity against A. ustus complex species, MECs ≥ 0.5 mg/L against Aspergillus insuetus and Aspergillus keveii strains, and was inactive against the Aspergillus alliaceus isolates tested (MEC90s ≥ 16 mg/L). All in all, ibrexafungerp shows encouraging in vitro results against cryptic species of Aspergillus and azole-susceptible and azole resistant strains of A. fumigatus, some of which are difficult to treat using the available therapeutic options.es_ES
dc.description.sponsorshipThis research was funded by Scynexis, Inc. (Jersey City, NJ, USA). O.R.-M. is supported by a fellowship from the Fondo de Investigación Sanitaria (grant FI14CIII/00025). J.C.S.-D. is supported by a fellowship from the Fondo de Investigación Sanitaria (grant FI17CIII/00027).es_ES
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAspergilluses_ES
dc.subjectCLSIes_ES
dc.subjectEUCASTes_ES
dc.subjectAntifungalses_ES
dc.subjectCryptices_ES
dc.subjectCyp51Aes_ES
dc.subjectIbrexafungerpes_ES
dc.titleIn Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID33804780es_ES
dc.format.volume7es_ES
dc.format.number3es_ES
dc.identifier.doi10.3390/jof7030232es_ES
dc.contributor.funderScynexis, Inc.
dc.description.peerreviewedes_ES
dc.identifier.e-issn2309-608Xes_ES
dc.relation.publisherversionhttps://doi.org/10.3390/jof7030232es_ES
dc.identifier.journalJournal Of Fungi (Basel, Switzerland)es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional